Compare AbbVie Inc (ABBV) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X Robotics and Artificial Intelligence ETF — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Global X Robotics and Artificial Intelligence ETF trades at $35.91. The key difference: AbbVie Inc pays a 2.72% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | BOTZ | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $41.63 |
52-Week Low | $184.85 | $31.99 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
BOTZ trades at $36.59, down 2.14% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, benefiting from reshoring trends and AI's expansion into physical automation. Recent news highlights robotics as the next trillion-dollar AI theme, with strong media coverage positioning BOTZ as a key player in the humanoid robotics and industrial automation space.
Outlook remains positive due to structural growth in robotics and AI, though valuation metrics are unavailable. Risks include sector concentration and reliance on AI adoption pace. Analyst sentiment is generally favorable, with the ETF well-positioned for long-term automation trends but vulnerable to tech sector volatility and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
